In a move set to transform the landscape of pharmaceutical research, Atombeat Inc., a leader in artificial intelligence for drug discovery, and BioDuro, a globally trusted Contract Research, Development, and Manufacturing Organization (CRDMO), have announced a strategic partnership. The collaboration will see the launch of a new, integrated platform designed to dramatically accelerate the discovery and development of peptide drugs.
This innovative platform seamlessly integrates Atombeat’s advanced AI-driven computational design with BioDuro’s extensive expertise in discovery chemistry, biology, and high-throughput synthesis. The partnership creates a powerful end-to-end workflow, from initial molecular design to the selection of a preclinical candidate, significantly reducing the time, cost, and risk traditionally associated with peptide drug discovery.
Atombeat’s proprietary software, Hermite®, and the RiDYMO® platform are at the heart of the new system. These technologies, which leverage advanced computer modeling and specialized data, enable the in silico exploration of over a trillion potential peptide compounds, built from more than 1,000 natural and non-natural amino acids. The platform rapidly filters and prioritizes these compounds based on key developability traits, such as membrane permeability, allowing scientists to focus only on the most promising candidates before any lab testing begins.
Once the design phase is complete, BioDuro takes over with its high-throughput synthesis capabilities. This allows for the parallel production of hundreds of high-purity peptides in as little as one week, ready for biological testing without the need for extensive purification steps. The integration of this rapid synthesis with readily available biology assays ensures swift validation of the AI-designed molecules.
“We are excited to advance peptide innovation through our strategic partnership with Atombeat,” said Dr. Armin Spura, CEO of BioDuro. “Atombeat brings extensive experience in AI-assisted drug design and optimization. Together, we aim to provide the industry with top services in peptide drug development, accelerating smarter and more efficient peptide research.”
Dr. Dongdong Wang, co-founder of Atombeat, echoed this sentiment, stating, “BioDuro’s deep expertise in peptide synthesis and testing complements our strengths in AI-driven drug design exceptionally well. By integrating AI with experimental processes, we are committed to building an intelligent, integrated platform for peptide drug discovery and evaluation. Our shared goal is to drive innovation and help meet unmet clinical needs worldwide.”
The new platform holds significant promise for a broad range of therapeutic areas, offering a more efficient and economical path to delivering high-quality cyclic peptides. By combining the strengths of both companies, this collaboration represents a major step forward in the use of AI to revolutionize pharmaceutical development.
![Online Scam Cases Continue to Rise Despite Crackdowns on Foreign Fraud Networks [Myanmar]](https://sumtrix.com/wp-content/uploads/2025/06/30-12-120x86.jpg "Online Scam Cases Continue to Rise Despite Crackdowns on Foreign Fraud Networks [Myanmar]")
